Testing a new treatment to protect the brain after a stroke
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
This study is testing a new treatment called tatCN19o to see if it can help protect the brain during and after a stroke, using small doses in rodent models to find out how well it works compared to current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurexis Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project ID | NIH-11058404 on NIH RePORTER |
What this research studies
This research focuses on developing a new peptide treatment called tatCN19o that aims to protect the brain during and after a stroke. The study will involve testing this treatment in rodent models of stroke to evaluate its effectiveness compared to existing therapies. The approach includes administering the peptide at very low doses and observing its neuroprotective effects over time. By using advanced testing methods, the researchers hope to gather reliable data on how well tatCN19o can prevent brain damage caused by ischemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a stroke or are at high risk for stroke, particularly those over 21 years old.
Not a fit: Patients who have not experienced a stroke or have conditions unrelated to cerebrovascular health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly reduces brain damage and improves recovery outcomes for stroke patients.
How similar studies have performed: Previous research has shown promising results with similar neuroprotective approaches, indicating potential for success in this novel treatment.
Where this research is happening
Aurora, United States
- Neurexis Therapeutics, INC. — Aurora, United States (Active)
Researchers
- Principal investigator: Goforth, Robyn L — Neurexis Therapeutics, INC.
- Study coordinator: Goforth, Robyn L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.